Abbott Gains CE Marks For New Tricuspid Device And Expanded Xience DES Indication
The next-generation TriClip G4 comes in more sizes than the original TriClip and features enhanced leaflet grasping features.
You may also be interested in...
Results from two trials confirm patients at high risk of bleeding treated with Abbott’s Xience stent can be safely treated with short regimens of dual antiplatelet therapy.
The company is sponsoring an early feasibility trial of the Intrepid transcatheter valve replacement system for patients with severe tricuspid regurgitation.
Edwards Lifesciences received the CE mark for its PASCAL transcatheter system for treating triscupid valve regurgitation, competing against Abbott’s newly CE-marked TriClip.